ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Therapy-induced senescent cancer cells as bidirectional regulators of antitumor immunity and resistance in the tumor microenvironment.Cell death & disease · 2026Review
- Intelligent CpG nanoplatforms for targeted cancer immunotherapy and immune remodeling.Frontiers in pharmacology · 2026Review
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Biomimetic Cell Membrane-coated Nanovaccines in Anti-tumor Immunotherapy.Theranostics · 2026Review
- A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes.Research (Washington, D.C.) · 2026Review
- X-ray-driven nanomotor with enhanced penetration and retention for carbon monoxide-amplified radioimmunotherapy of advanced colorectal cancer.Materials today. Bio · 2025Article
- Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.Materials today. Bio · 2025Review
- Engineered cellular drug delivery: Strategies and applications.Materials today. Bio · 2025Review
- Cancer Cell Membrane-Coated NPs as a Biomimetic Strategy for Precision Tumor Therapy.Pharmaceutics · 2025Review
- Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Materials today. Bio · 2025Review
- Nature-Inspired Nanostructures from Multiple-Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor-Targeted Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Natural vaccine adjuvants from traditional Chinese medicines: Mechanisms to applications.Acta pharmaceutica Sinica. B · 2025Review
- A multifunctional biomimetic nanoplatform combined with immune checkpoint blockade for triple-negative breast cancer immunotherapy through inhibiting polarization of M2 macrophages.Journal of nanobiotechnology · 2025Article
- Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.International journal of molecular sciences · 2025Review
- Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) againstBioactive materials · 2025Article
- Novel strategies for nanovaccine application in breast cancer treatment.Frontiers in pharmacology · 2025Review
- Insights into tumor vaccines for elderly individuals in the context of immunosenescence.Frontiers in immunology · 2025Review
- Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals.Science advances · 2024Article
- Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Senescent cancer cells are endowed with high immunogenic potential that has been leveraged to elicit antitumor immunity and potentially complement anticancer therapies. However, the efficacy of live senescent cancer cell-based vaccination is limited by interference from immunosuppressive senescence-associated secretory phenotype and pro-tumorigenic capacity of senescent cells. Here, a senescent cancer cell-based nanovaccine with strong immunogenicity and favorable potential for immunotherapy is reported. The biomimetic nanovaccine integrating a senescent cancer cell membrane-coated nanoadjuvant outperforms living senescent cancer cells in enhancing dendritic cells (DCs) internalization, improving lymph node targeting, and enhancing immune responses. In contrast to nanovaccines generated from immunogenic cell death-induced tumor cells, senescent nanovaccines facilitate DC maturation, eliciting superior antitumor protection and improving therapeutic outcomes in melanoma-challenged mice with fewer side effects when combined with αPD-1. The study suggests a versatile biomanufacturing approach to maximize immunogenic potential and minimize adverse effects of senescent cancer cell-based vaccination and advances the design of biomimetic nanovaccines for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.